D.E. Shaw & Co’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
D.E. Shaw & Co's NVO Position: Q3 2026 in Review
D.E. Shaw & Co reduced its Novo Nordisk (NVO) stake by 92% in Q3 2026, selling an estimated $29.7M and leaving 53,514 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3226.
D.E. Shaw & Co first reported a position in NVO in Q2 2013 and has held it in 41 quarters since. The position peaked at $179M in Q1 2025. 1,227 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- D.E. Shaw & Co held 53,514 shares of Novo Nordisk worth $2.03M as of Q3 2026.
- D.E. Shaw & Co sold 644,053 Novo Nordisk shares in Q3 2026, an estimated $29.7M.
- Novo Nordisk made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q3 2026, its #3226 holding.
- D.E. Shaw & Co first reported a position in Novo Nordisk in Q2 2013 and has held it in 41 quarters since.
- D.E. Shaw & Co's Novo Nordisk position peaked at $179M in Q1 2025.
- 1,227 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.